Arcutis Biotherapeutics, Inc. ARQT Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s business segments — net loss?
- Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — net loss of -$11.3M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s business segments — net loss changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s business segments — net loss increased by 54.9% year-over-year, from -$25.06M to -$11.3M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s business segments — net loss?
- Over 2 years (2022 to 2024), Arcutis Biotherapeutics, Inc.'s business segments — net loss has grown at a -32.9% compound annual growth rate (CAGR), from -$311.46M to -$140.04M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the reportable segment after deducting all operating expenses, interest, and taxes from total revenues. A negative value indicates that the segment's costs and investments in growth or research exceed its generated revenue. It serves as a primary indicator of the segment's current path toward operational sustainability and financial viability.